A new risk locus in CHCHD5 for hypertension and obesity in a Chinese child population: a cohort study

Lijun Wu,1 Liwang Gao,1 Xiaoyuan Zhao,1 Meixian Zhang,1 Jianxin Wu,2 Jie Mi1

ABSTRACT
Objective Coiled-coil-helix-coiled-coil-helix domain containing 5 (CHCHD5), a mitochondrial protein, is involved in the oxidative folding process in the mitochondrial intermembrane space. A previous study identified a hypertension-related single nucleotide polymorphism (SNP), rs3748024, in CHCHD5 in adults, but there are no reports regarding the association between CHCHD5 and obesity, which is a known risk factor for hypertension. The aim of the present study is to investigate the associations of the SNP rs3748024 with hypertension and obesity.

Design Cohort study.

Setting Institute of Pediatrics in China.

Participants We genotyped the SNP rs3748024 in the Beijing Child and Adolescent Metabolic Syndrome study. A total of 3503 children participated in the study.

Primary and secondary outcome measures Genotyping of rs3748024 was conducted using the TaqMan Allelic Discrimination Assay. Lipids and glucose were analysed by an automatic biochemical analyser using a kit assay. The levels of adipocytokines (leptin, adiponectin and resistin) were measured by ELISA techniques.

Results There was a statistically significant association between rs3748024 and systolic blood pressure (SBP) (β=−0.039, 95% CI −0.070 to −0.007, p=0.044) after correction for multiple testing. The SNP was also significantly associated with BMI (β=−0.286, 95% CI −0.551 to −0.021, p=0.043), obesity (OR=0.828, 95% CI 0.723 to 0.949, p=0.018) and triglycerides (β=−0.039, 95% CI −0.070 to −0.007, p=0.044) after correction for multiple testing.

Conclusions We demonstrate for the first time that the SNP rs3748024 in CHCHD5 is associated with SBP, BMI, obesity and triglycerides in Chinese children. Our study identifies a new risk locus for hypertension and obesity in a child population. The function of CHCHD5 remains to be further studied to help elucidate the pathogenic role of CHCHD5 in hypertension and obesity.

INTRODUCTION
In recent years, the prevalence of hypertension and obesity has been increasing in most parts of the world, and these two diseases are major threats to public health.1,2 Childhood hypertension and obesity strongly predispose to adult hypertension and obesity.3,4,5

Previously, multiple single nucleotide polymorphisms (SNPs) related to hypertension or obesity have been identified by genome-wide association studies.6-9 However, almost no SNPs are associated with both hypertension and obesity.

Coiled-coil-helix-coiled-coil-helix domain containing 5 (CHCHD5), a mitochondrial protein encoded by CHCHD5, is located at chromosome 2q13.10 CHCHD5 is homologous to yeast Mic14, which affects mitochondrial oxygen consumption.11 New evidence suggests that CHCHD5 is a substrate of the oxido-reductase Mia40, which promotes an oxidative folding process in the mitochondrial intermembrane space.12 The maintenance of redox balance in the mitochondria depends on the mitochondrial oxidative folding pathway and is crucial for normal cell physiology.

Evidence from a previous study suggested that the SNP rs3748024 in CHCHD5 was significantly associated with hypertension in Taiwanese adults,13 but no study has been conducted to confirm that this SNP contributes to hypertension in other populations, especially in children.

Because obesity is a known risk factor for hypertension and CHCHD protein family members play a vital role in a wide variety of physiological and pathological processes,14 we investigated the associations of the SNP rs3748024 with both hypertension and obesity.
We genotyped this SNP in Chinese children who had participated in the population-based Beijing Child and Adolescent Metabolic Syndrome (BCAMS) study. The present study attempts to provide an analysis of epidemiological and genetic data towards the associations of the SNP in \textit{CHCHD5} with hypertension and obesity.

**METHODS**

**Population**

Subjects were recruited from a cross-sectional population-based survey, termed the BCAMS study, in 2004. The survey included a questionnaire, medical examination and anthropometric measurement in a representative sample (n=19593, 50% boys) of children in Beijing aged 6–18 years. Anthropometric measurements included height, weight, waist circumference and fat mass percentage. Within this large group of children in whom venepuncture blood samples were collected, 1229 were diagnosed as obese using the Chinese age-specific and sex-specific body mass index (BMI) cut-offs (online supplementary table S1). We used BMI as a measure of obesity because BMI is significantly associated with adolescent subcutaneous fat and is an indicator of childhood and adolescent obesity. An additional 2274 non-obese children, including 655 overweight and 1619 normal-weight children, were randomly selected by the SPSS statistical software (V.18.0; SPSS). The participants were then divided into two groups. One group comprised 1045 children with elevated blood pressure (EBP, including prehypertension and hypertension). EBP includes systolic blood pressure (SBP) or diastolic blood pressure (DBP) that is elevated. The other group comprised 2458 children with normal blood pressure as diagnosed by the blood pressure reference cut-offs for Chinese children and adolescents (online supplementary table S2). The BCAMS study was approved by the ethics committee of the Capital Institute of Pediatrics. We obtained written informed consent from parents or guardians.

**Measurement of BMI and blood pressure**

BMI was calculated as the person’s weight (kg) divided by the squared height in metres. After a rest period of 5 min, blood pressure (BP) was measured by auscultation using a standard clinical sphygmomanometer. DBP was determined by the fourth Korotkoff sound (K4), and SBP was determined by the onset of the ‘tapping’ Korotkoff sounds (K1). Three consecutive measurements were performed, and the mean of the three readings was used for analysis.

**Measurement of biochemical analyses and genotyping**

The level of fasting plasma glucose (FPG) was measured using the hexokinase method. The levels of lipids were measured using the enzymatic methods for triglycerides (TGs) and total cholesterol (TC) measurements, and the clearance methods for high-density lipoprotein cholesterol (HDL) and low-density lipoprotein cholesterol (LDL) measurements. The measurements were performed using a kit assay (SEKISUI Medical Technology, Tokyo, Japan) and an automatic biochemical analyser (Hitachi 7060). The levels of adipocytokines (leptin, adiponectin and resistin) were measured by ELISA techniques.

Genomic DNA was isolated from peripheral white blood cells using the salt fractionation method. Genotyping of rs3748024 was conducted using the TaqMan Allelic Discrimination Assay with the GeneAmp 7900 Sequence Detection System (Applied Biosystems, Foster City, CA, USA). The genotyping call rate for the SNP was 98.3%. We repeated 70 samples randomly for the SNP to validate the accuracy of the genotyping and observed 100% concordance between the results of the two tests. We also sent 30 samples to direct sequencing and observed 100% concordance between the two genotyping methods.

**Statistical analyses**

Categorical variables were presented as percentages and continuous variables were presented as mean±SD. The Hardy-Weinberg equilibrium was assessed using the $\chi^2$ test. Adjusted ORs for EBP were performed by logistic regression with genotypes, age, gender and BMI as the independent variables. ORs for obesity were performed by logistic regression with genotypes, age and gender as the independent variables. A linear regression model was used to investigate the associations of the SNP with SBP, DBP, BMI, lipids, FPG and adipocytokines (leptin, adiponectin and resistin). The data were analysed using SPSS statistical software. p Value <0.05 was used to indicate statistically significant differences. The false discovery rate (FDR) approach was used to correct for multiple testing. Supposing that there are a total of $m$ p values, the original p value was arranged from small to large: \(p(1), p(2), \ldots, p(m)\), stringent \(p(i)=(p(i)\times m)/i\). In brief, the stringent p value was considered statistically significant only if it was less than 0.05 for the FDR. Power calculation was performed using Quanto software (http://hydra.usc.edu/gxe/) according to the sample size, effect size ($\beta$ or OR), inheritance mode and allele frequency.

**RESULTS**

The basic characteristics of the study participants are summarised in online supplementary table S3. The SNP rs3748024 (chromosome: 2:112588836) lies in an intron (location of the intron: 112584650–112588865) of the gene and three genotypes of the SNP are GG, GC and CC. The SNP occurs downstream of the transcription start site and is not within a splice sequence. The SNP is also an expression quantitative trait locus (eQTL) in adipose (subcutaneous), heart (left ventricle) or artery (aorta) (data from GTEx Portal, https://gtexportal.org/home/). The significance values and effect sizes of the \(cis\) eQTLs are shown in online supplementary table S4. We genotyped the SNP rs3748024 in \textit{CHCHD5} in the cohort, and the genotype of the SNP (the numbers of GG, GC and CC are 2190, 1113 and 140, respectively) was tested to be in Hardy-Weinberg
equilibrium (p=0.924). The associations of the SNP rs3748024 with SBP, DBP and EBP are shown in table 1A,B. There were statistically significant associations of rs3748024 with SBP, DBP and EBP after adjustment for age and gender. As obesity is a known risk factor for hypertension, we also adjusted for BMI besides age and gender. After correction for multiple testing, the SNP rs3748024 was significantly associated with SBP (β=−0.853, 95% CI −1.482 to −0.024, p=0.044) under an additive model adjusted for age, gender and BMI.

We further analysed the associations of the SNP with BMI and obesity. There were statistically significant associations of rs3748024 with BMI (β=−0.286, 95% CI −0.551 to −0.021, p=0.043) and obesity (OR=0.828, 95% CI 0.723 to 0.949, p=0.018) under an additive model after adjustment for age and gender (table 2). Online supplementary figure S1 shows the means of SBP, DBP, BMI and obesity (%) in groups with different genotypes of rs3748024.

We also analysed the associations of the SNP with lipids, plasma glucose and adipocytokines (online supplementary table S5). After correction for multiple testing, the SNP rs3748024 was significantly associated with TG (β=−0.039, 95% CI −0.070 to −0.007, p=0.044) under an additive model adjusted for age, gender and BMI. No statistical significance was found between the SNP and TC, HDL, LDL, FPG and adipocytokines after correction for multiple testing. Studies with greater sample size are needed to confirm these associations.

### Table 1 Associations of SNP rs3748024 with SBP, DBP and EBP

#### (A) Associations of rs3748024 with SBP and DBP

| Phenotype | Additive model | Mean±SD | β*  | 95% CI* | Stringent p value* | Power | β†  | 95% CI† | Stringent p value† | Power |
|-----------|----------------|---------|------|---------|-------------------|-------|------|---------|-------------------|-------|
| SBP       | GG             | 108±14  | −1.260 | −1.996 to −0.524 | 0.005  | 0.844 | −0.853 | −1.482 to −0.024 | 0.044  | 0.521 |
|           | GC             | 107±14  |       |         |                   |       |      |         |                   |       |      |
|           | CC             | 106±15  |       |         |                   |       |      |         |                   |       |      |
| DBP       | GG             | 68±10   | −0.067 | −1.225 to −0.019 | 0.032  | 0.056 | −0.421 | −0.982 to 0.087 | 0.286  | 0.280 |
|           | GC             | 67±10   |       |         |                   |       |      |         |                   |       |      |
|           | CC             | 67±10   |       |         |                   |       |      |         |                   |       |      |

Those highlighted in bold indicate that the associations showed statistical significance.

*Adjusted for age and gender.
†Adjusted for age, gender and body mass index.

DBP, diastolic blood pressure; EBP, elevated blood pressure, including prehypertension and hypertension; NBP, normal blood pressure; SBP, systolic blood pressure.

### Table 2 Associations of rs3748024 with BMI and obesity

| Additive model | Additive model | BMI | Obesity |
|----------------|----------------|-----|---------|
| Mean±SD        | Stringent p value, 95% CI* | Power | N (obese) | N (NW) |
|                |                 |     |          |         | Stringent p value, 95% CI* | Power |
| GG             | 22.02±4.92      | 0.043 | 0.475 | 798 | 974 | 0.018 | 0.998 |
| GC             | 21.73±4.87      |       |       | 364 | 540 |       |       |
| CC             | 21.67±5.67      | 0.043 | 0.475 | 46  | 73  | 0.018 | 0.998 |

Those highlighted in bold indicate that the associations showed statistical significance.

*Adjusted for age and gender.

BMI, body mass index; NW, normal weight.
DISCUSSION

CHCHD5 belongs to the CHCHD protein family and is involved in the oxidative folding process in the mitochondrial intermembrane space. A previous study has shown that CHCHD5 is related to hypertension in adults, but there are no reports regarding the association between CHCHD5 and obesity, which is a known risk factor for hypertension.

Because childhood hypertension and obesity strongly predispose to adult hypertension, we investigated the genetic susceptibility of the SNP rs3748024 in children. Because obesity is a known risk factor for hypertension, we also adjusted for BMI besides age and gender. Our results indicated that the significant association between the SNP and SBP remained after adjustment for BMI. Therefore, we further investigated the associations of the SNP with BMI and obesity. The results showed positive correlations.

Because the CHCHD protein family members play a vital role in a wide variety of physiological and pathological processes and it is not clear whether the function of CHCHD5 affects endocrine and metabolic processes, we investigated the associations of the SNP in CHCHD5 with lipids, glucose and adipokines. The results indicated that the SNP was significantly associated with TG after multiple testing.

Our results indicated that the SNP rs3748024 was significantly associated with BMI and obesity, but the significant associations of the SNP with SBP and TG were independent of BMI. It suggested that although obesity is a risk factor for hypertension and hyperlipidaemia, the SNP rs3748024, as a new risk locus in CHCHD5 for SBP and TG, was not related to BMI. However, the molecular mechanism by which this SNP associates with these phenotypes remains to be studied. Given the marginal significance of the association in this study, we are cautious in assuming the biological/clinical relevance of this SNP. It is possible that this SNP is not the ‘causal’ mutation, and some other SNPs in the region might explain the associations.

In addition, a large percentage of children had been identified as hypertensive because of the high proportion of obesity in our participants. Obesity increases the prevalence of hypertension in children. However, in our study, 72.4% of the overweight/obese participants did not have EBP, and 6.4% of the normal weight participants had EBP. The blood pressure measurements were taken at the same time of day, and white coat hypertension might not have been completely avoided. This is a limitation of our study.

CONCLUSIONS

We demonstrate for the first time that the SNP rs3748024 in CHCHD5 is associated with SBP, BMI, obesity and TG in Chinese children. These novel findings identify a new risk locus associated with hypertension and obesity in children. The function of CHCHD5 remains to be further studied to help elucidate the pathogenic role of CHCHD5 in hypertension and obesity.

REFERENCES

1. Wang Y, Lobstein T. Worldwide trends in childhood overweight and obesity. Int J Pediatr Obes 2006;1:11–25.
2. Mittal BV, Singh AK. Hypertension in the developing world: challenges and opportunities. Am J Kidney Dis 2010;55:590–8.
3. Chen X, Wang Y. Tracking of blood pressure from childhood to adulthood: a systematic review and meta-regression analysis. Circulation 2008;117:3171–80.
4. Simmonds M, Burch J, Llewellyn A, et al. The use of measures of obesity in childhood for predicting obesity and the development of obesity-related diseases in adulthood: a systematic review and meta-analysis. Health Technol Assess 2015;19:1–336.
5. Lloyd LJ, Langley-Evans SC, McMullen S. Childhood obesity and risk of the adult metabolic syndrome: a systematic review. Int J Obes 2012;36:1–11.
6. Lu X, Wang L, Lin X, et al. Genome-wide association study in Chinese identifies novel loci for blood pressure and hypertension. Hum Mol Genet 2015;24:865–74.
7. Newton-Cheh C, Johnson T, Gateva V, et al. Genome-wide association study identifies eight loci associated with blood pressure. Nat Genet 2009;41:666–76.
8. Macleod JA, Walters GB, Gudbjartsson DF, et al. Genome-wide association study yields new sequence variants at seven loci that associate with measures of obesity. Nat Genet 2009;41:18–24.
9. Meyre D, Delplanque J, Chèvre JC, et al. Genome-wide association study for early-onset and morbid adult obesity identifies three new risk loci in European populations. Nat Genet 2009;41:157–9.
10. Banci L, Bertini I, Giofi-Baffoni S, et al. Structural characterization of CHCHD5 and CHCHD7: two atypical human twin CXCR3 proteins. J Struct Biol 2012;180:190–200.
11. Longen S, Bien M, Birnbaum K, et al. Systematic analysis of the twin ccr5(c) protein family. J Mol Biol 2009;393:566–88.
12. Mordas A, Tokatidis K. The MIA pathway: a key regulator of mitochondrial oxidative protein folding and biogenesis. Acc Chem Res 2015;48:2191–9.
13. Chung C-M, Fann CSJ, Chen J-W, et al. Genome-wide scan for young-onset hypertension in Han Chinese in Taiwan. J Hypertens 2011;29:e36.
14. Cavallaro G. Genome-wide analysis of eukaryotic twin CX9C proteins. Mol Biosyst 2010;6:2459–70.

15. Mi J, Cheng H, Hou DQ, et al. [Prevalence of overweight and obesity among children and adolescents in Beijing in 2004]. Zhonghua Liu Xing Bing Xue Za Zhi 2006;27:474–9.

16. Ji CY, Cy J. Report on childhood obesity in China (1)—body mass index reference for screening overweight and obesity in Chinese school-age children. Biomed Environ Sci 2005;18:390–400.

17. Himes JH, Dietz WH. Guidelines for overweight in adolescent preventive services: recommendations from an expert committee. The expert committee on clinical guidelines for overweight in adolescent preventive services. Am J Clin Nutr 1994;59:307–16.

18. Mi J, Wang TY, Meng LH, et al. Development of blood pressure reference standards for Chinese children and adolescents. Chin J Evid Based Pediatr 2010;5:4–14.

19. Araki S, Dobashi K, Kubo K, et al. High molecular weight, rather than total, adiponectin levels better reflect metabolic abnormalities associated with childhood obesity. J Clin Endocrinol Metab 2006;91:5113–6.

20. Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J Roy Stat Soc B 1995;57:289–300.